HumanFirst, a leader in cloud-based software and artificial intelligence (AI) powered insights for drug development, has announced a pioneering precision measures platform. The platform is designed to aid pharma and biotech companies in seamlessly incorporating patient-centric measures into their clinical research. Valued for its potential to revolutionize drug development, the platform comes at a time when life science organizations are under immense pressure to enhance R&D efficiencies.

Regulatory Support and Industry Shift towards AI

Recent endorsements from regulatory authorities like the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have encouraged rapid investments in AI-powered strategies for drug development. This support, coupled with a growing need for participant diversity in clinical trials, is setting the stage for groundbreaking changes in the industry.

HumanFirst’s Advanced Atlas Platform

To meet the industry’s demands, HumanFirst has evolved its Atlas platform into a comprehensive cloud-based enterprise solution. The upgraded platform encompasses Digital Health Technologies (DHTs), questionnaires, and fluid-based markers, among other measures. It offers multiple functionalities like Atlas Network, Atlas Connect, Atlas Insights, and the HumanFirst Institute.

Atlas Network: A Comprehensive Evidence Platform

Atlas Network is touted as the most comprehensive platform for precision measures, curating more than 7,500 pieces of evidence. The platform is already aiding more than 1,700 clinical trials and allows for the selection of the right measures from a massive database.

Atlas Connect: For Proprietary Research Data

Atlas Connect provides a private, secure workflow solution that facilitates organizational management of proprietary research data, thereby accelerating the development of protocols.

Atlas Insights: AI-Powered Analysis

Atlas Insights offers AI-powered insights and curated evidence, aimed at enabling differentiated asset and portfolio strategies for organizations.

HumanFirst Institute: Training and Empowerment

The HumanFirst Institute is designed to educate and empower research teams, providing them with essential knowledge and training to effectively deploy precision measures.

“We at HumanFirst have been, and continue to be, the single largest database of AI-powered biomarkers and COAs,” said Andy Coravos, co-founder and CEO of HumanFirst. Coravos emphasized the importance of AI in drug development, stating, “As navigating AI has become an imperative for all of pharma, I’m excited that with today’s announcement, HumanFirst now offers a solution for the entire enterprise to reduce costs, accelerate development, and bring better treatments to market faster.”

  Andy Coravos, HumanFirst